348 related articles for article (PubMed ID: 23603345)
1. Dihydropyrimidine dehydrogenase gene (DPYD) polymorphism among Caucasian and non-Caucasian patients with 5-FU- and capecitabine-related toxicity using full sequencing of DPYD.
Saif MW
Cancer Genomics Proteomics; 2013; 10(2):89-92. PubMed ID: 23603345
[TBL] [Abstract][Full Text] [Related]
2. A case report of a severe fluoropyrimidine-related toxicity due to an uncommon DPYD variant.
De Falco V; Natalicchio MI; Napolitano S; Coppola N; Conzo G; Martinelli E; Zanaletti N; Vitale P; Giunta EF; Vietri MT; Vitiello PP; Ciardiello D; Marinaccio A; De Vita F; Ciardiello F; Troiani T
Medicine (Baltimore); 2019 May; 98(21):e15759. PubMed ID: 31124962
[TBL] [Abstract][Full Text] [Related]
3. Dihydropyrimidine dehydrogenase gene variation and severe 5-fluorouracil toxicity: a haplotype assessment.
Amstutz U; Farese S; Aebi S; Largiadèr CR
Pharmacogenomics; 2009 Jun; 10(6):931-44. PubMed ID: 19530960
[TBL] [Abstract][Full Text] [Related]
4. High-throughput genotyping by DHPLC of the dihydropyrimidine dehydrogenase gene implicated in (fluoro)pyrimidine catabolism.
Gross E; Seck K; Neubauer S; Mayr J; Hellebrand H; Ratanaphan A; Lutz V; Stockinger H; Kiechle M
Int J Oncol; 2003 Feb; 22(2):325-32. PubMed ID: 12527930
[TBL] [Abstract][Full Text] [Related]
5. [Dihydropyrimidine déhydrogenase (DPD) deficiency screening and securing of fluoropyrimidine-based chemotherapies: Update and recommendations of the French GPCO-Unicancer and RNPGx networks].
Loriot MA; Ciccolini J; Thomas F; Barin-Le-Guellec C; Royer B; Milano G; Picard N; Becquemont L; Verstuyft C; Narjoz C; Schmitt A; Bobin-Dubigeon C; Harle A; Paci A; Poinsignon V; Quaranta S; Evrard A; Hennart B; Broly F; Fonrose X; Lafay-Chebassier C; Wozny AS; Masskouri F; Boyer JC; Etienne-Grimaldi MC
Bull Cancer; 2018 Apr; 105(4):397-407. PubMed ID: 29486921
[TBL] [Abstract][Full Text] [Related]
6. DPYD genotype-guided dose individualisation of fluoropyrimidine therapy in patients with cancer: a prospective safety analysis.
Henricks LM; Lunenburg CATC; de Man FM; Meulendijks D; Frederix GWJ; Kienhuis E; Creemers GJ; Baars A; Dezentjé VO; Imholz ALT; Jeurissen FJF; Portielje JEA; Jansen RLH; Hamberg P; Ten Tije AJ; Droogendijk HJ; Koopman M; Nieboer P; van de Poel MHW; Mandigers CMPW; Rosing H; Beijnen JH; Werkhoven EV; van Kuilenburg ABP; van Schaik RHN; Mathijssen RHJ; Swen JJ; Gelderblom H; Cats A; Guchelaar HJ; Schellens JHM
Lancet Oncol; 2018 Nov; 19(11):1459-1467. PubMed ID: 30348537
[TBL] [Abstract][Full Text] [Related]
7. The Prevalence of DPYD*9A(c.85T>C) Genotype and the Genotype-Phenotype Correlation in Patients with Gastrointestinal Malignancies Treated With Fluoropyrimidines: Updated Analysis.
Maharjan AS; McMillin GA; Patel GK; Awan S; Taylor WR; Pai S; Frankel AE; Nelson C; Wang B; Hosein PJ; Singh AP; Khushman M
Clin Colorectal Cancer; 2019 Sep; 18(3):e280-e286. PubMed ID: 31160238
[TBL] [Abstract][Full Text] [Related]
8. Relationship between single nucleotide polymorphisms and haplotypes in DPYD and toxicity and efficacy of capecitabine in advanced colorectal cancer.
Deenen MJ; Tol J; Burylo AM; Doodeman VD; de Boer A; Vincent A; Guchelaar HJ; Smits PH; Beijnen JH; Punt CJ; Schellens JH; Cats A
Clin Cancer Res; 2011 May; 17(10):3455-68. PubMed ID: 21498394
[TBL] [Abstract][Full Text] [Related]
9. Clinical implementation of pre-treatment DPYD genotyping in capecitabine-treated metastatic breast cancer patients.
Stavraka C; Pouptsis A; Okonta L; DeSouza K; Charlton P; Kapiris M; Marinaki A; Karapanagiotou E; Papadatos-Pastos D; Mansi J
Breast Cancer Res Treat; 2019 Jun; 175(2):511-517. PubMed ID: 30746637
[TBL] [Abstract][Full Text] [Related]
10. A candidate gene study of capecitabine-related toxicity in colorectal cancer identifies new toxicity variants at DPYD and a putative role for ENOSF1 rather than TYMS.
Rosmarin D; Palles C; Pagnamenta A; Kaur K; Pita G; Martin M; Domingo E; Jones A; Howarth K; Freeman-Mills L; Johnstone E; Wang H; Love S; Scudder C; Julier P; Fernández-Rozadilla C; Ruiz-Ponte C; Carracedo A; Castellvi-Bel S; Castells A; Gonzalez-Neira A; Taylor J; Kerr R; Kerr D; Tomlinson I
Gut; 2015 Jan; 64(1):111-20. PubMed ID: 24647007
[TBL] [Abstract][Full Text] [Related]
11. New advances in DPYD genotype and risk of severe toxicity under capecitabine.
Etienne-Grimaldi MC; Boyer JC; Beroud C; Mbatchi L; van Kuilenburg A; Bobin-Dubigeon C; Thomas F; Chatelut E; Merlin JL; Pinguet F; Ferrand C; Meijer J; Evrard A; Llorca L; Romieu G; Follana P; Bachelot T; Chaigneau L; Pivot X; Dieras V; Largillier R; Mousseau M; Goncalves A; Roché H; Bonneterre J; Servent V; Dohollou N; Château Y; Chamorey E; Desvignes JP; Salgado D; Ferrero JM; Milano G
PLoS One; 2017; 12(5):e0175998. PubMed ID: 28481884
[TBL] [Abstract][Full Text] [Related]
12. Prospective DPYD genotyping to reduce the risk of fluoropyrimidine-induced severe toxicity: Ready for prime time.
Lunenburg CATC; Henricks LM; Guchelaar HJ; Swen JJ; Deenen MJ; Schellens JHM; Gelderblom H
Eur J Cancer; 2016 Feb; 54():40-48. PubMed ID: 26716401
[TBL] [Abstract][Full Text] [Related]
13. [Review of methods for determination of dihydropyrimidine dehydrogenase and possible application in screening previous chemotheraphy with 5-fluorouracil].
Ostapowicz A; Dołegowska B
Przegl Lek; 2012; 69(9):694-7. PubMed ID: 23401991
[TBL] [Abstract][Full Text] [Related]
14. Influence of dihydropyrimidine dehydrogenase gene (DPYD) coding sequence variants on the development of fluoropyrimidine-related toxicity in patients with high-grade toxicity and patients with excellent tolerance of fluoropyrimidine-based chemotherapy.
Kleibl Z; Fidlerova J; Kleiblova P; Kormunda S; Bilek M; Bouskova K; Sevcik J; Novotny J
Neoplasma; 2009; 56(4):303-16. PubMed ID: 19473056
[TBL] [Abstract][Full Text] [Related]
15. Complete DPYD genotyping combined with dihydropyrimidine dehydrogenase phenotyping to prevent fluoropyrimidine toxicity: A retrospective study.
De Metz C; Hennart B; Aymes E; Cren PY; Martignène N; Penel N; Barthoulot M; Carnot A
Cancer Med; 2024 Mar; 13(6):e7066. PubMed ID: 38523525
[TBL] [Abstract][Full Text] [Related]
16. Uncommon dihydropyrimidine dehydrogenase mutations and toxicity by fluoropyrimidines: a lethal case with a new variant.
Del Re M; Quaquarini E; Sottotetti F; Michelucci A; Palumbo R; Simi P; Danesi R; Bernardo A
Pharmacogenomics; 2016; 17(1):5-9. PubMed ID: 26651493
[TBL] [Abstract][Full Text] [Related]
17. A DPYD variant (Y186C) specific to individuals of African descent in a patient with life-threatening 5-FU toxic effects: potential for an individualized medicine approach.
Saif MW; Lee AM; Offer SM; McConnell K; Relias V; Diasio RB
Mayo Clin Proc; 2014 Jan; 89(1):131-136. PubMed ID: 24388031
[TBL] [Abstract][Full Text] [Related]
18. Capecitabine-based treatment of a patient with a novel DPYD genotype and complete dihydropyrimidine dehydrogenase deficiency.
Henricks LM; Siemerink EJM; Rosing H; Meijer J; Goorden SMI; Polstra AM; Zoetekouw L; Cats A; Schellens JHM; van Kuilenburg ABP
Int J Cancer; 2018 Jan; 142(2):424-430. PubMed ID: 28929491
[TBL] [Abstract][Full Text] [Related]
19. Genetic markers of toxicity from capecitabine and other fluorouracil-based regimens: investigation in the QUASAR2 study, systematic review, and meta-analysis.
Rosmarin D; Palles C; Church D; Domingo E; Jones A; Johnstone E; Wang H; Love S; Julier P; Scudder C; Nicholson G; Gonzalez-Neira A; Martin M; Sargent D; Green E; McLeod H; Zanger UM; Schwab M; Braun M; Seymour M; Thompson L; Lacas B; Boige V; Ribelles N; Afzal S; Enghusen H; Jensen SA; Etienne-Grimaldi MC; Milano G; Wadelius M; Glimelius B; Garmo H; Gusella M; Lecomte T; Laurent-Puig P; Martinez-Balibrea E; Sharma R; Garcia-Foncillas J; Kleibl Z; Morel A; Pignon JP; Midgley R; Kerr D; Tomlinson I
J Clin Oncol; 2014 Apr; 32(10):1031-9. PubMed ID: 24590654
[TBL] [Abstract][Full Text] [Related]
20. Toxic death-case after capecitabine + oxaliplatin (XELOX) administration: probable implication of dihydropyrimidine deshydrogenase deficiency.
Ciccolini J; Mercier C; Dahan L; Evrard A; Boyer JC; Richard K; Dales JP; Durand A; Milano G; Seitz JF; Lacarelle B
Cancer Chemother Pharmacol; 2006 Aug; 58(2):272-5. PubMed ID: 16292536
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
